Neurizon Therapeutics Limited has released a press release.
Appendix 4E and 2025 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE
- FDA Review Timeline Extended for NUZ-001 IND Clinical Hold
- Neurizon Secures Loan Against 2025 R&D Tax Rebate
- Neurizon Submits Clinical Hold Complete Response to FDA
- Positive feedback from FDA on strategy to lift clinical hold
Later from Neurizon Therapeutics
- R&D Tax Incentive Advance & Overseas Finding Approval
- Neurizon Raises $5m via Institutional Placement
- FDA Lifts Clinical Hold on NUZ-001
- Australian Patent Granted for NUZ-001
- Neurizon to present Q1 FY2026 Results
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics